Use of Oral isotretinoin on wound healing in hair transplanted patients

Oral isotretinoin in hair transplant patients and its effect on wound healing - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/12/077733

Enrollment

Registered

2024-12-06

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: ORAL ISOTRETINOIN: Group A will receive oral isotretinoin at a dose of 0.5 mg once daily starting 1 month prior to the procedure and will be continued for 6 months Control Intervention1

Eligibility

Inclusion criteria

Inclusion criteria: 1.Androgenetic alopecia patients undergoing hair transplant procedure. 2.Age group 23 to 50 years of both the genders. 3.Patients having seborrheic scalp with history of itching, folliculitis or pustules on the scalp.

Exclusion criteria

Exclusion criteria: 1.History of allergic reaction to the drug. 2.Presence of any contraindication to isotretinoin like psychiatric disorders, pseudotumor cerebri, pancreatitis, hyperlipidemic conditions, hearing impairment, inflammatory bowel diseases, vision impairment.

Design outcomes

Primary

Measure	Time frame
To investigate the potential positive effects of oral isotretinoin on wound healing in hair transplant patients.Timepoint: After 6 Months	—

Secondary

Measure	Time frame
To assess the impact of isotretinoin on post-hair transplant graft survival, scar quality of donor and recipient area, and patient satisfaction.Timepoint: After 6 Months	—

Countries

India

Contacts

Public ContactDr Madura C

CUTIS Academy of Cutaneous Sciences

maduradr@gmail.com9632741998

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026